Skip to main content

Acute GvHD

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
NCT01530256 | PHASE 1 | INTERVENTIONAL

The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.

Trial Information
5 Sites
3 Participants
Recruiting
18 Years to 7 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

City of Hope
Duarte,California,United States,91010
Loyola Medical Center
Maywood,Illinois,United States,60153
Washington University
Saint Louis,Missouri,United States,63110
The Ohio State University
Columbus,Ohio,United States,43210
Virginia Commonwealth University
Richmond,Virginia,United States,23298

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov